注射用去氧氟尿苷治疗晚期胃癌、乳腺癌的单中心、随机、单盲、剂量探索Ⅱa期及人体药代动力学临床试验
[Translation] A single-center, randomized, single-blind, dose-finding phase IIa and human pharmacokinetic clinical trial of deoxyfluridine for injection in the treatment of advanced gastric cancer and breast cancer
(1)初步探索注射用去氧氟尿苷高、中、低不同剂量治疗晚期乳腺癌、胃癌的有效性和安全性; (2)观察乳腺癌、胃癌等患者单剂量和多剂量静脉滴注注射用去氧氟尿苷后药物的体内经时过程,估计其药代动力学参数,并与患者静脉滴注5-FU后的药代动力学参数比较,为临床用药提出指导。
[Translation] (1) Preliminary exploration of the efficacy and safety of high, medium and low doses of deoxyfluridine for injection in the treatment of advanced breast cancer and gastric cancer; (2) Observation of single-dose and multi-dose intravenous drip in patients with breast cancer and gastric cancer The pharmacokinetic parameters of the drug in vivo after deoxyfluridine for injection were estimated and compared with the pharmacokinetic parameters of patients after intravenous infusion of 5-FU to provide guidance for clinical drug use.
100 Clinical Results associated with Hangzhou Aida Pharmaceuticals Co. Ltd.
0 Patents (Medical) associated with Hangzhou Aida Pharmaceuticals Co. Ltd.
100 Deals associated with Hangzhou Aida Pharmaceuticals Co. Ltd.
100 Translational Medicine associated with Hangzhou Aida Pharmaceuticals Co. Ltd.